List of Excipients in Branded Drug NITROGLYCERIN IN DEXTROSE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Baxter Healthcare Company	NITROGLYCERIN IN DEXTROSE	nitroglycerin	0338-1047	ALCOHOL
Baxter Healthcare Company	NITROGLYCERIN IN DEXTROSE	nitroglycerin	0338-1047	CITRIC ACID MONOHYDRATE
Baxter Healthcare Company	NITROGLYCERIN IN DEXTROSE	nitroglycerin	0338-1047	DEXTROSE MONOHYDRATE
Baxter Healthcare Company	NITROGLYCERIN IN DEXTROSE	nitroglycerin	0338-1047	HYDROCHLORIC ACID
Baxter Healthcare Company	NITROGLYCERIN IN DEXTROSE	nitroglycerin	0338-1047	PROPYLENE GLYCOL
Baxter Healthcare Company	NITROGLYCERIN IN DEXTROSE	nitroglycerin	0338-1047	SODIUM HYDROXIDE

Nitroglycerin in Dextrose: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 20, 2026

Nitroglycerin in dextrose is an established intravenous vasodilator formulation used in acute coronary syndromes, perioperative blood-pressure control, and congestive heart failure. Its commercial opportunity is driven less by active-ingredient exclusivity than by container compatibility, adsorption control, ready-to-use dosing, stability, and hospital supply reliability.

The strongest product strategy is a low-sorption, ready-to-administer presentation that reduces compounding steps and preserves delivered nitroglycerin concentration. Dextrose is a functional vehicle, not a meaningful source of long-term product differentiation by itself.

What is nitroglycerin in dextrose used for?

Nitroglycerin is an organic nitrate that releases nitric oxide and produces predominantly venous vasodilation at lower doses, with arterial vasodilation at higher doses. Intravenous nitroglycerin is used when rapid titration is required, including:

• Acute angina and acute coronary syndromes
• Perioperative hypertension
• Controlled hypotension during surgery
• Acute congestive heart failure with elevated filling pressures
• Hypertensive emergencies involving myocardial ischemia

Commercial nitroglycerin injection is commonly supplied as a concentrate that must be diluted in 5% dextrose injection or 0.9% sodium chloride injection before intravenous administration. Ready-to-use nitroglycerin-in-dextrose bags remove that dilution step.

Typical infusion rates begin at approximately 5 micrograms per minute and are titrated according to blood pressure, symptoms, and clinical response. Product labeling controls the administration method, dilution instructions, dosage increments, and tubing requirements. [1]

What does dextrose contribute to the formulation?

Dextrose has four principal functions:

1. It provides an injectable aqueous vehicle.
2. It contributes osmolality and allows a clinically familiar infusion format.
3. It supports compatibility with standard hospital infusion practices.
4. It permits a ready-to-use bag presentation at a defined nitroglycerin concentration.

Dextrose is not required for nitroglycerin pharmacology. Sodium chloride injection is also used as a diluent. The commercial value of dextrose is therefore linked to formulation presentation, hospital workflow, and compatibility rather than therapeutic differentiation.

Which excipients are used in nitroglycerin in dextrose?

The core formulation normally contains nitroglycerin, dextrose, and water for injection. Some products may include pH-adjusting agents or other formulation components, depending on the manufacturer and dosage form. The exact excipient profile must be taken from the applicable product label and chemistry, manufacturing, and controls file.

Formulation element	Primary function	Commercial relevance
Nitroglycerin	Active vasodilator	Requires accurate low-dose delivery and concentration control
Dextrose, commonly D5W	Vehicle and tonicity contributor	Supports premixed infusion products
Water for injection	Solvent	Controls injectable quality and sterility
pH adjustment, if used	Maintains chemical stability	Can affect degradation, compatibility, and container interaction
Container and tubing system	Delivery system	May materially affect delivered dose through adsorption

The most important “excipient” issue is not the dextrose itself. It is the interaction between nitroglycerin and the product-contact system.

How does nitroglycerin adsorption affect formulation design?

Nitroglycerin is known to adsorb to polyvinyl chloride tubing and other contact surfaces. The resulting loss can reduce the amount of drug reaching the patient, particularly during initial priming and at low infusion rates. Product labels have historically warned that nitroglycerin may be absorbed by PVC tubing and have recommended non-absorptive or low-sorption administration sets. [1]

This creates a formulation and device opportunity in four areas:

• Low-sorption bag films
• Non-PVC administration sets
• Defined priming procedures
• Container-closure systems with validated drug recovery

A product may have acceptable assay and stability in the commercial container while still producing variable delivered dose through the administration set. A complete development program therefore needs to measure:

• Initial concentration after manufacture
• Concentration after storage
• Recovery after contact with the bag
• Recovery after contact with tubing
• Loss during priming
• Delivered concentration over the intended infusion period
• Compatibility with common pumps, filters, and connectors

A low-sorption product supported by validated administration instructions has more defensible value than a standard D5W formulation with no delivery-system differentiation.

What concentrations and dosage forms create commercial opportunities?

Nitroglycerin in dextrose can be developed in several presentations.

Presentation	Primary customer	Strategic value
Concentrated vial or ampoule	Hospital pharmacy	Lowest manufacturing complexity; requires dilution
Premixed small-volume bag	Emergency department, ICU, operating room	Reduces preparation and dosing errors
Premixed large-volume bag	ICU and perioperative care	Supports continuous infusion and reduces pharmacy workload
Ready-to-use syringe	Emergency and procedural settings	Fast deployment; higher packaging and stability demands
Pharmacy bulk package	Institutional compounding	Lower unit cost but more operational controls
Dual-container or closed-system format	Hospitals seeking reduced manipulation	Can support workflow and contamination-control claims

Common clinical concentrations are expressed in micrograms per milliliter or milligrams per container. A commercial program should avoid excessive concentration proliferation. Hospitals generally benefit from a limited portfolio that covers routine titration while minimizing inventory complexity.

A practical portfolio could include:

• One concentrated vial for pharmacy dilution
• One ready-to-use premix for emergency and critical-care use
• One larger bag for prolonged infusions

The optimal concentration depends on infusion-pump capabilities, hospital protocols, storage limits, and whether the product is intended to replace pharmacy-prepared admixtures.

What patent claims could protect nitroglycerin in dextrose?

The active ingredient has been used clinically for decades, so new exclusivity is unlikely to arise from nitroglycerin itself. A modern patent estate would need to focus on formulation, packaging, manufacturing, or delivery.

Formulation patents

Potential formulation claims could address:

• A defined nitroglycerin concentration in dextrose
• pH ranges that improve stability
• Specified degradation limits after storage
• Reduced adsorption to container-contact materials
• Compatibility with a defined administration set
• Premixed stability without bedside dilution
• Low particulate and extractables profiles

A patent directed only to nitroglycerin in D5W at a conventional concentration would face substantial novelty and obviousness risk. Stronger claims would require a demonstrated technical effect, such as materially improved drug recovery, extended shelf life, or improved container compatibility.

Container and delivery-system patents

The strongest patent opportunity is often the combination of formulation and package:

• Nitroglycerin in a specified low-sorption multilayer bag
• A bag-and-tubing system with defined recovery performance
• A primed administration set that limits dose loss
• A light-protective container with validated stability
• A closed transfer system that avoids manual dilution

These claims should be supported by comparative data against PVC and conventional commercial systems. A patent that covers only a generic non-PVC bag may be vulnerable if the material selection is routine. A claim tied to measured nitroglycerin recovery and a specific material architecture is more commercially relevant.

Manufacturing-method patents

Manufacturing claims may address:

• Controlled deoxygenation or oxygen exposure
• Addition order and mixing conditions
• Temperature-controlled filling
• Nitroglycerin adsorption control during processing
• Aseptic filling of low-dose premixed solutions
• In-process assay controls for concentration uniformity

Process patents are useful when they reduce degradation or improve content uniformity, but they may have limited blocking power if competitors can reach the same product through a different process.

What is the Orange Book status of nitroglycerin in dextrose?

Nitroglycerin injection is an old, established prescription product. The commercial landscape is primarily generic and hospital-supply driven rather than protected by a new-drug patent estate.

The relevant regulatory questions are:

• Whether a specific product is approved under an NDA, ANDA, or another pathway
• Whether the product is listed as a reference or generic product
• Whether any patents or regulatory exclusivities are listed for the specific reference product
• Whether the proposed premixed presentation has a separate approved product record
• Whether the product is supplied as a drug, pharmacy-compounded preparation, or outsourcing-facility product

The FDA Orange Book is the controlling source for patent and exclusivity information tied to listed products. [2] A company should not assume that a concentrate and a premixed dextrose bag have identical regulatory or patent positions. They may have different product records, sponsors, labeling, and approval pathways.

For an abbreviated new drug application, the principal regulatory burden is likely to involve pharmaceutical equivalence, bioequivalence where applicable, sterility, stability, container compatibility, extractables and leachables, and labeling conformity. Because the product is administered intravenously, manufacturing controls and sterility assurance are central commercial barriers.

When does nitroglycerin in dextrose lose exclusivity?

The active ingredient has no meaningful modern composition-of-matter exclusivity. Market entry is instead governed by product-specific patents, regulatory exclusivity, manufacturing readiness, and supply contracts.

For an established nitroglycerin injection product:

Exclusivity category	Commercial assessment
Active-ingredient patent	Generally expired or commercially irrelevant
Standard formulation patent	Likely expired or difficult to enforce unless tied to a newer presentation
Method-of-use patent	Limited value for established indications and generic hospital use
Container or delivery patent	Potentially relevant for differentiated premix products
FDA approval exclusivity	Product-specific and dependent on approval pathway
Manufacturing know-how	Often more important than patent term
Supply agreement	Can delay practical substitution without creating legal exclusivity

Paragraph IV litigation is more likely when a sponsor obtains patents on a differentiated premix, delivery system, or stability profile than when it markets a conventional nitroglycerin-in-dextrose solution. A generic applicant could challenge listed patents by certifying that they are invalid, unenforceable, or not infringed. The commercial value of such litigation depends on whether the patent covers the marketed product rather than an optional package component.

What generic entry risks exist?

Generic entry risk is high for conventional nitroglycerin injection because:

• The molecule is well established.
• Clinical use is standardized.
• The product is generally administered in hospitals.
• Substitution can occur through pharmacy procurement.
• The core formulation is comparatively simple.
• Active-ingredient exclusivity does not provide a durable barrier.

Risk is lower for a differentiated product if it has:

• A validated low-sorption container system
• Ready-to-use status with a meaningful workflow advantage
• Superior shelf life
• A proprietary bag film or administration set
• Reliable availability during shortages
• Strong hospital formulary adoption
• A defensible patent covering the full commercial configuration

The principal competitive threat is not always a direct copy. Hospitals may substitute among concentrated vials, pharmacy-prepared admixtures, premixed bags, and products from different suppliers.

Which companies compete in nitroglycerin injection?

Competition has historically included large injectable-drug manufacturers and hospital-supply companies, including Pfizer/Hospira, Fresenius Kabi, Hikma, Sandoz, and other regional generic suppliers. Product availability varies by country, NDC, presentation, and supply status.

Competitive differentiation generally rests on:

• Price per delivered dose
• Availability of vials and premixed bags
• Contract pricing
• Shelf life
• Container compatibility
• Packaging format
• Shortage performance
• Hospital pharmacy labor savings

The relevant market is institutional rather than retail. Purchasing decisions are often made through group purchasing organizations, health-system contracts, and pharmacy procurement teams. A product with a modest unit-price premium may still win if it reduces dilution, relabeling, waste, or infusion-set complications.

What FDA regulatory issues affect commercial development?

FDA-regulated development must address sterile injectable manufacturing, container-closure integrity, stability, labeling, and compatibility. The product may be pursued as an ANDA if the reference-product and dosage-form requirements are satisfied, or under another pathway when the proposed presentation does not fit conventional generic requirements.

Key technical packages include:

• Sterility and endotoxin control
• Particulate matter testing
• Assay and related-substances methods
• Container-closure integrity
• Stability under labeled storage conditions
• Photostability, where applicable
• Extractables and leachables
• In-use stability after opening or connection
• Compatibility with administration sets
• Nitroglycerin recovery after priming and infusion

USP sterile-compounding standards are relevant when hospitals or outsourcing facilities prepare nitroglycerin admixtures rather than purchasing a finished premixed product. [3] FDA’s outsourcing-facility framework under section 503B can influence the competitive environment, particularly during shortages or when hospitals rely on compounded sterile preparations. [4]

How strong is the patent estate for nitroglycerin in dextrose?

The baseline patent estate is weak for conventional nitroglycerin in D5W. The molecule and basic intravenous use are old. Patent strength improves only when the product includes a measurable technical advance.

Protection strategy	Patent strength	Commercial usefulness
Nitroglycerin as an active ingredient	Very low	Minimal
Nitroglycerin in conventional D5W	Low	Limited
Defined stability profile	Moderate if unexpected	Useful
Low-sorption container system	Moderate to strong if data-supported	High
Bag plus tubing combination	Moderate	High if broadly adopted
Manufacturing process	Moderate	Depends on detectability
New indication	Low to moderate	Limited for hospital generic market
Ready-to-use presentation	Low alone; higher with technical effect	High operational value

The best strategy combines patent protection with trade secrets. Patents can cover the package, material composition, and performance parameters. Trade secrets can protect filling conditions, process controls, supplier specifications, and quality testing methods.

What licensing and partnership opportunities exist?

Licensing opportunities are more likely to involve manufacturing and delivery technology than the nitroglycerin molecule.

Potential partners include:

• Injectable drug manufacturers with sterile-fill capacity
• Bag-film suppliers with low-sorption materials
• Administration-set manufacturers
• Contract development and manufacturing organizations
• Hospital purchasing groups
• 503B outsourcing facilities
• Regional generic companies with established regulatory infrastructure

A licensing deal should be evaluated against four commercial assets:

1. Regulatory approval or a credible abbreviated-approval pathway
2. Proven container and tubing compatibility
3. Manufacturing capacity and shortage resilience
4. Hospital contracts or formulary access

A formulation patent without manufacturing capacity has limited value. Conversely, a reliable premix supply program may attract partners even where patent protection is narrow.

What revenue exposure and market opportunities exist?

Nitroglycerin is generally a lower-revenue product than chronic cardiovascular medicines, but it has high clinical criticality. Revenue exposure is concentrated in hospital and emergency-care channels.

Commercial opportunity is strongest in:

• Ready-to-use premixed bags
• Shortage-resistant supply
• Low-sorption delivery systems
• Simplified emergency-department formats
• Perioperative and cardiac-care contracts
• Reduced-waste packaging
• International markets with limited local sterile injectable capacity

A manufacturer should model revenue by units, not only by milligrams. A low-volume, high-concentration vial and a premixed bag may contain similar total drug but have different pricing, labor savings, procurement preferences, and substitution risk.

Key Takeaways

• Nitroglycerin in dextrose is an established sterile intravenous product with limited active-ingredient exclusivity.
• Dextrose is primarily a vehicle and tonicity component, not a strong differentiator.
• Adsorption to PVC and other contact materials is the central formulation and delivery-system issue.
• The strongest commercial product is a ready-to-use, low-sorption premix with validated delivered-dose performance.
• Conventional formulation patents are likely weak unless supported by unexpected stability or recovery data.
• Container, tubing, manufacturing, and package-combination claims offer the most credible new patent opportunities.
• Generic entry risk is high for conventional products and lower for technically differentiated premixes.
• FDA approval, sterility assurance, stability, container compatibility, and supply reliability will often matter more than molecule-level patent rights.
• Licensing value is concentrated in sterile manufacturing capacity, low-sorption packaging, and hospital distribution.

FAQs

Is nitroglycerin in dextrose the same as nitroglycerin in normal saline?

No. Both dextrose injection and sodium chloride injection can be used as diluents, but the products differ in vehicle composition, osmolality, packaging, and compatibility requirements.

Does nitroglycerin require a non-PVC infusion set?

Product labeling has historically warned that nitroglycerin can adsorb to PVC. A low-sorption or non-PVC administration set can improve delivered-dose consistency, particularly during initial infusion and at low flow rates.

Can a premixed nitroglycerin bag receive patent protection?

Yes, but a conventional nitroglycerin-in-D5W composition may be difficult to protect. Stronger claims would connect the formulation to a specific container, tubing system, stability result, or reduced-adsorption performance.

Is nitroglycerin in dextrose eligible for 503B outsourcing?

A 503B facility may compound eligible sterile products subject to statutory requirements, current good manufacturing practice, FDA registration, reporting, and applicable bulk-drug and clinical-need conditions. The precise eligibility depends on the product and regulatory status. [4]

What is the main commercial risk for a new nitroglycerin premix?

The main risk is substitution by established vials, pharmacy-prepared admixtures, or competing premixed bags. A new product must show procurement, labor, stability, compatibility, or supply advantages that justify conversion costs.

References

1. U.S. Food and Drug Administration. (n.d.). Nitroglycerin injection prescribing information. FDA-approved product labeling.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. United States Pharmacopeia. (2023). General Chapter <797>: Pharmaceutical compounding - sterile preparations. United States Pharmacopeial Convention.

4. U.S. Food and Drug Administration. (n.d.). Outsourcing facilities. https://www.fda.gov/drugs/human-drug-compounding/outsourcing-facilities-cols-section-503b``